AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.
Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.
AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.
In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.
This umbrella review of recent systematic reviews and meta-analyses compared the effectiveness and underlying mechanisms of various prevention and treatment strategies to regulate blood glucose.
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes in patients with type 2 diabetes and chronic kidney disease at high CV risk.
EASD 2018 Following a review of the latest evidence, the EASD and the ADA introduced new recommendations on managing hyperglycemia in T2DM, including specific drug classes for some patients and enhancing medication adherence.
EASD 2018 Increased fasting glucose, higher BMI and impaired insulin sensitivity were detectable up to 10 years before the diagnosis of diabetes as well as prediabetes.
EASD 2018 Weight gain between the age of 10 and adulthood is associated with T2DM risk. Overweight children at age 10 appear to be at lower risk for developing T2DM than children who are regular weight at age 10 and then later become overweight as adults.
EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.
ESC 2018 In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.